Role of high molecular weight hyaluronic acid in postmenopausal vaginal discomfort.
OBJECTIVE
Aim of the present study was to quantify the intensity of vulvovaginal symptoms before and after treatment with high molecular weight hyaluronic acid (HA), to test the tolerability and safety of the product, to evaluate the effect on the quality of life and the compliance to the treatment.


METHODS
This was a double-blind randomized placebo-controlled study. In seven months we enrolled 36 post-menopausal women, equally distributed in placebo and active group. The evaluation was based on at least three atrophy-related signs and on the patient reported symptoms. After the written informed consent, the participants were instructed to apply the gel (drug or placebo) daily. Three days after the end of the treatment the patients received a final examination to evaluate the progress of symptoms, the presence of any adverse events and their correlation with the treatment.


RESULTS
Self-evaluation scales and investigator evaluation showed that the vaginal dryness was significantly reduced both in placebo and in the active group; however, high molecular weight HA was the only active treatment in reducing significantly itching and burning (P<0.02 and <0.04 respectively). Both treatments significantly reduced vaginal atrophy (P<0.001), erythema (P<0.01 placebo and P<0.001 HA) and vaginal dryness (P<0.001), but HA treatment was significantly more effective on the first two symptoms. Both treatments were very well tolerated and compliance of the treatment was very high.


CONCLUSIONS
High molecular weight HA could be effective in subjective and objective improvement of postmenopausal vaginal atrophy providing a good compliance. No adverse events occurred during the entire period of the study.
Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy.
E F
EF
Grimaldi
S
S
Restaino
S
S
Inglese
L
L
Foltran
A
A
Sorz
G
G
Di Lorenzo
S
S
Guaschino
D001284:Atrophy / Q000188:drug therapy; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000627:therapeutic use*; D008875:Middle Aged; D008970:Molecular Weight; D017698:Postmenopause; D014621:Vagina / Q000187:drug effects* / Q000473:pathology*; D014623:Vaginal Diseases / Q000188:drug therapy*
D006820:Hyaluronic Acid